<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05042817</url>
  </required_header>
  <id_info>
    <org_study_id>VesicalMorphine</org_study_id>
    <nct_id>NCT05042817</nct_id>
  </id_info>
  <brief_title>Effetc of Intrathecal Morphine on Vesical Function After Caesarean Section</brief_title>
  <official_title>Effetc of Intrathecal Morphine on Vesical Function After Caesarean Section</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Liege</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Liege</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The enhanced recovery anesthesia concept has been widely adopted, included for c-sectio. This&#xD;
      concept includes avoidance or early withdrawal of the bladder catheter. However, this is&#xD;
      challenged by the use of intrathecal morphine that is recommended in order to provide a long&#xD;
      lasting post-operative analgesia.&#xD;
&#xD;
      In the present study, we study The effect of iintrathecal morphine on the vesical function&#xD;
      after a caesarean section&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to first voiding after surgery</measure>
    <time_frame>until the end of the study, an average of 6 months</time_frame>
    <description>Vesical function1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>number of attempts</measure>
    <time_frame>until the end of the study, an average of 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Vesical function2</measure>
    <time_frame>until the end of the study, an average of 6 months</time_frame>
    <description>Bladder scan before and after urination and surgery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vesical function3</measure>
    <time_frame>until the end of the study, an average of 6 months</time_frame>
    <description>Urodynamic study before and after surgery</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Analgesia</condition>
  <arm_group>
    <arm_group_label>Morphine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>50 mg prilocaine + 2.5 mcg sufentanil + 100 mcg morphine (0.1ml)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NaCl 0.9%</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>50 mg prilocaine + 2.5 mcg sufentanil + 0.1 ml saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine</intervention_name>
    <description>The effect of iintrathecal morphine on the vesical function after a caesarean section</description>
    <arm_group_label>Morphine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NaCl 0.9%</intervention_name>
    <description>NaCl 0.9%</description>
    <arm_group_label>NaCl 0.9%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>50 mg prilocaine + 2.5 mcg sufentanil</intervention_name>
    <description>50 mg prilocaine + 2.5 mcg sufentanil</description>
    <arm_group_label>Morphine</arm_group_label>
    <arm_group_label>NaCl 0.9%</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Elective cesarean section&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Anticoagulation&#xD;
&#xD;
          -  Platelet anomaly&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Philippe Gautiuer, MD</last_name>
    <phone>042843820</phone>
    <phone_ext>+32</phone_ext>
    <email>gautierphilippe0@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Philippe Gautier, MD</last_name>
    <phone>042843820</phone>
    <phone_ext>+32</phone_ext>
    <email>gautierphilippe0@gmail.com</email>
  </overall_contact_backup>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 16, 2021</study_first_submitted>
  <study_first_submitted_qc>September 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 13, 2021</study_first_posted>
  <last_update_submitted>September 6, 2021</last_update_submitted>
  <last_update_submitted_qc>September 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Liege</investigator_affiliation>
    <investigator_full_name>Jean Fran√ßois Brichant</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sufentanil</mesh_term>
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Prilocaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

